Seems to me a lot of positive momentum, excluding Q4 sales in this announcement.
12.5% increase in US hospitals using Xbio.
3M in better position with dedicated sales force and direct to consumer activity commencing in the first 2 quarters of 2020.
Skin cancer trial moving to Phase 3 at good pace for commencement in 2021.
European regulatory delays are impacting the entire medical device community.
I remain very positive about the long term prospects for the company and have a great deal of faith in the CEO.
Have a great weekend everyone.
Ann: Q4 2019 Quarterly Update and Appendix 4C, page-19
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $58.43M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 20.0¢ | 19.0¢ | $5.034K | 26.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| NXS (ASX) Chart |